NCT06264674

Brief Summary

The CLI-05993AB6-03 Study is an interventional study designed to investigate the safety and efficacy of a new low global warming potential propellant (HFA-152a) compared to the currently approved one (HFA-134a) in the medication (CHF5993) in patients with moderate to severe asthma

Trial Health

98
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Strong global presence with extensive site network
Enrollment
827

participants targeted

Target at P75+ for phase_3 asthma

Timeline
Completed

Started Nov 2023

Geographic Reach
14 countries

118 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 13, 2023

Completed
14 days until next milestone

Study Start

First participant enrolled

November 27, 2023

Completed
3 months until next milestone

First Posted

Study publicly available on registry

February 20, 2024

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 18, 2025

Completed
6 days until next milestone

Study Completion

Last participant's last visit for all outcomes

February 24, 2025

Completed
Last Updated

April 14, 2026

Status Verified

April 1, 2026

Enrollment Period

1.2 years

First QC Date

November 13, 2023

Last Update Submit

April 9, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Relative change from pre-dose Forced Expiratory Volume in one second with (FEV1) (Safety Assessment to evaluate of the potential bronchoconstriction of the study treatment)

    Relative change from pre-dose in FEV1 at the 10 min post-dose timepoint

    Day 1

Secondary Outcomes (10)

  • To complete the evaluation of FEV1 and the potential for bronchoconstriction of the study treatment (relative change from pre-dose FEV1)

    Day 1, Day 7, Week 4, Week 12

  • To complete the evaluation of FEV1 and the potential for bronchoconstriction of the study treatment (absolute change from pre-dose FEV1)

    Day 1, Day 7, Week 4, Week 12

  • To complete the evaluation of FEV1 and the potential for bronchoconstriction of the study treatment (number and percentage of subjects with a relative decrease from pre-dose in FEV1)

    Day 1, Day 7, Week 4, Week 12

  • To complete the evaluation of FEV1 and the potential for bronchoconstriction of the study treatment (Absolute and relative changes from baseline in pre-dose FEV1)

    Day 1, Day 7, Week 4, Week 12

  • To complete the evaluation of FEV1 and the potential for bronchoconstriction of the study treatment (Change from pre-dose in FEV1)

    Day 1, Day 7, Week 12

  • +5 more secondary outcomes

Other Outcomes (4)

  • To measure the safety and tolerability of CHF5993 pMDI HFA-152a in terms of Adverse Events (AEs) / Adverse Drug Reactions (ADRs).

    Through study completion, an average of 1 year

  • To measure the safety and tolerability of CHF5993 pMDI HFA-152a in terms of number of Adverse Events (AEs) of particular interest.

    Through study completion, an average of 1 year

  • To measure the safety and tolerability of CHF5993 pMDI HFA-152a in terms of incident rate of Adverse Events (AEs) of particular interest.

    Through study completion, an average of 1 year

  • +1 more other outcomes

Study Arms (2)

Inhaler CHF5993 200/6/12.5 μg pMDI HFA-152a

EXPERIMENTAL

Active ingredients: BDP/FF/GB 200/6/12.5 μg per actuation; Excipients: HFA-152a propellant.

Drug: CHF5993 200/6/12.5 μg pMDI HFA-152a

Inhaler CHF5993 200/6/12.5 μg pMDI HFA-134a

ACTIVE COMPARATOR

Active ingredients: BDP/FF/GB 200/6/12.5 μg per actuation; Excipients: HFA-134a propellant.

Drug: Inhaler CHF5993 200/6/12.5 μg pMDI HFA-134a

Interventions

Pressurised Metered Dose Inhaler-2 inhalations twice daily

Also known as: HFA-152a propellant
Inhaler CHF5993 200/6/12.5 μg pMDI HFA-152a

Pressurised Metered Dose Inhaler-2 inhalations twice daily

Also known as: HFA-134a propellant
Inhaler CHF5993 200/6/12.5 μg pMDI HFA-134a

Eligibility Criteria

Age18 Years - 75 Years
Sexall(Gender-based eligibility)
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subject's written informed consent obtained prior to any study related procedure;
  • Male and female adults aged ≥ 18 and ≤ 75;
  • Body mass index (BMI) within the range of 18.0 to 35.0 kg/m2 inclusive;
  • Non-smokers or ex-smokers who smoked \< 10 pack-years (pack-years = the number of cigarette packs per day x the number of years) and stopped smoking \> 1 year (6 months for e-cigarettes) prior to screening;
  • Diagnosis of asthma: physician-diagnosed asthma for at least
  • months and with diagnosis before the age of 50 years;
  • Stable asthma therapy: a stable treatment with medium/high doses of inhaled corticosteroids (ICS) + long-acting β-agonist (LABA) + long-acting muscarinic antagonist (LAMA) (fixed or free combination) or medium/high doses of ICS+LABA (fixed or free combination) for at least 4 weeks before screening (medium and high-dose ICS defined as BDP non-extrafine \> 500-1000 μg and \> 1000 μg respectively, or estimated clinical comparable dose).
  • Subjects must have a cooperative attitude and the ability to be trained to use correctly the pMDI inhalers and e-Diary, to be able to read/write, to be able to perform the required outcomes measurements (e.g., technically acceptable spirometry, e-Diary completion) and the ability to understand the risks involved.

You may not qualify if:

  • History of near fatal asthma, hospitalisation for asthma in intensive care unit which in the judgement of the Investigator may place the subject at undue risk, emergency room access for asthma in the previous 6 months before enrolment;
  • Asthma exacerbation requiring systemic corticosteroids (SCS) or emergency room admission or hospitalisation within 4 weeks prior to study entry and/or during the run-in period (to be checked again prior to randomisation);
  • Non-permanent asthma: exercise-induced, seasonal asthma (as the only asthma-related diagnosis) not requiring daily asthma control medecine

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (118)

"IPSMCPP-D-R Veleva" EOOD

Burgas, Bulgaria

Location

Medical Center "Zdrave -1"

Kozloduy, Bulgaria

Location

"AIPSMP Yuskyan Aliosman" Ltd

Momchilgrad, Bulgaria

Location

Ambulatory for Specialized Outpatient Medical Care - Individual Practice

Rousse, 7000, Bulgaria

Location

Specialized Hospital For Active Treatment Of Pneumo-Phthisiatric Diseases Dr. Dimitar Gramatikov - Ruse Ltd.

Rousse, 7002, Bulgaria

Location

Specialized Hospital For Active Treatment Of Pneumo-Phthisiatric Diseases Dr. Dimitar Gramatikov

Rousse, 7002, Bulgaria

Location

Multiprofile Hospital For Active Treatment - Shumen AD,

Shumen, 9700, Bulgaria

Location

Diagnostic Consultative Centre 1-

Sliven, 8801, Bulgaria

Location

MHAT Sliven to MMA Sofia

Sliven, Bulgaria

Location

University First Multiprofile Hospital for Active Treatment -Sofia "St. Joan Krastilel" EAD

Sofia, 1142, Bulgaria

Location

Multiprofile Hospital For Active Treatment "Knyaginya Klementina" Sofia EAD,

Sofia, 1233, Bulgaria

Location

Medical Center Hera EOOD, 20 Klisura str., fl. 2,

Sofia, 1510, Bulgaria

Location

Multi-profile Hospital for Active Treatment Zdraveto 2012 Ltd.,

Sofia, 1618, Bulgaria

Location

Diagnostics and Consultation Center Convex EOOD

Sofia, 1680, Bulgaria

Location

"Medical Center Sun i Zdrave"

Sofia, Bulgaria

Location

Medical Center "Syrtuin" Ltd

Sofia, Bulgaria

Location

Medical Center "New Rehabilitation Center" Ltd

Stara Zagora, 6003, Bulgaria

Location

ASMP MC Kissiovi Ltd.

Varna, 9000, Bulgaria

Location

Hornmed, s.r.o

Brno, 618 00, Czechia

Location

Nemocnice Jihlava, Plicní oddělení

Jihlava, 586 01, Czechia

Location

MediTrial s.r.o.

Jindřichův Hradec, 37701, Czechia

Location

Pneumology dpt., Poliklinika Budějovická, MEDICON a.s.

Prague, 140 00, Czechia

Location

Pneumology dpt., Fakultní Thomayerova nemocnice

Prague, 14000, Czechia

Location

Prvni plicni ambulance s.r.o

Prague, 190 00, Czechia

Location

Plicní středisko Teplice s.r.o.

Teplice, 415 01, Czechia

Location

Geo Hospitals Gardabani Multiprofile Medical Centre

Gardabani, Georgia

Location

Geo Hospitals Gurjaani Multiprofile Medical Centre

Gurjaani, Georgia

Location

Geo Hospitals Sagarejo Multiprofile Medical Centre

Sagarejo, Georgia

Location

Medihelp Ltd

Samtredia, Georgia

Location

Imermedi-Imereti Regional Medical Center. (Terjolamedi) Ltd.

T'erjola, 2400, Georgia

Location

Curatio, Jsc

Tbilisi, 0114, Georgia

Location

Geo Hospitals Tbilisi Multiprofile Medical Center

Tbilisi, 0144, Georgia

Location

First Medical Center LLC

Tbilisi, 0180, Georgia

Location

GEO HOSPITALS Zestaphoni Ambulatory Centre

Zestaponi, Georgia

Location

Studienpraxis Berlin-Brandenburg Cornelia Seelbinder Und Lennart Schaper GbR

Berlin, 10119, Germany

Location

Lungenpraxis Hohenzollerndamm

Berlin, 10717, Germany

Location

Klinische Forschung Berlin

Berlin, 10787, Germany

Location

Policum Berlin Studien GmbH Friedenau

Berlin, 12157, Germany

Location

Institut für Allergie- und Asthmaforschung

Berlin, 12159, Germany

Location

Dr. med. Thomas Ginko Facharzt für Lungen- und Bronchialheilkunde

Bonn, 53119, Germany

Location

Neudorfer Lungenpraxis

Duisburg, 47057, Germany

Location

IKF Pneumologie Frankfurt Clinical Research Centre Respiratory Medicine IFS - Interdisziplinäres Facharztzentrum

Frankfurt, 60596, Germany

Location

Athanasios Xanthopoulos Praxis für Pneumologie

Fürstenwalde, 15517, Germany

Location

Praxis für Pneumologie und Allergologie

Leipzig, 04299, Germany

Location

POIS Sachsen GmbH

Leipzig, 04347, Germany

Location

KLB Gesundheitsforschung Lübeck GmbH

Lübeck, 23552, Germany

Location

SMO Zentrum für klinische Studien

Magdeburg, 39120, Germany

Location

Pneumologisches Studienzentrum München

München, 12159, Germany

Location

Siteworks Prüfzentrum Schleswig GmbH

Schleswig, 24837, Germany

Location

Lungenpraxis Witten

Witten, 58452, Germany

Location

"George Papanikolaou" General Hospital of Thessaloniki

Thessaloniki, 570 10, Greece

Location

University of Debrecen, Infectology Clinic Pulmonary unit

Debrecen, Hungary

Location

Erzsébet Gondozóház

Gödöllő, H-2100, Hungary

Location

BKS Research Kft.,

Hatvan, H-3000, Hungary

Location

Revamed Kft

Nyíregyháza, H-4400, Hungary

Location

INFER-MED Kft

Pécs, Hungary

Location

Árkádia Egészségközpont

Szombathely, H-9700, Hungary

Location

Clinica Malattie Respiratorie e allergologia IRCCS Ospedale Policlinico San Martino

Genova, 16132, Italy

Location

University of Messina, Allergy and Clinical Immunology Unit, Department of Experimental and Clinical Medicine

Messina, 98125, Italy

Location

Azienda Ospedaliera dei colli - Ospedale Monaldi

Naples, 80131, Italy

Location

EB FlevoResearch BV

Almere Stad, 1311 RL, Netherlands

Location

Amphia Hospital

Breda, 4818 CK, Netherlands

Location

Gelre Hospitals Zutphen (Gelre ziekenhuizen Zutphen)

Zutphen, 7207 AE, Netherlands

Location

Prywatny gabinet internistyczno-alergologiczny prof. Zenon Siergiejko

Bialystok, 15-010, Poland

Location

Centrum Medycyny Oddechowej, Mróz Spółka Jawna

Bialystok, 15-044, Poland

Location

Uniwersytet Medyczny w Bialymstoku Wydzial Nauk o Zdrowiu Klinika Alergologii i Chorób Wewnetrznych

Bialystok, 15-276, Poland

Location

Prywatna praktyka lekarska. Gabinet pediatryczno - alergologiczny

Bialystok, 15-430, Poland

Location

Vitamed Galaj I Cichomski Sp. J.

Bydgoszcz, 85-079, Poland

Location

Centrum Nowoczesnych Terapii "Dobry Lekarz"

Krakow, 31-011, Poland

Location

Private Health Care MEDYK-KRAK Sp. o.o.

Krakow, 31-455, Poland

Location

Diamond Clinic Spółka z ograniczoną odpowiedzialnością

Krakow, 31-559, Poland

Location

Małopolskie Centrum Alergologii sp. z o.o.

Krakow, 31-624, Poland

Location

ATOPIA Niepubliczny Zakład Opieki Zdrowotnej

Krakow, 35-159, Poland

Location

Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego

Lodz, 90-153, Poland

Location

Makowskie Centrum Medyczne MCM "Hamernia" Maków Podhalański

Maków Podhalański, 34-220, Poland

Location

Ostrowieckie Centrum Medyczne Spółka Cywilna Anna Olech-Cudzik, Krzysztof Cudzik

Ostrowiec Świętokrzyski, 27-400, Poland

Location

Prywatny Gabinet Lekarski Małgorzata Pawlukiewicz

Rzeszów, 35-051, Poland

Location

Clinmedica Research Sp. Z O.O.

Skierniewice, 96-100, Poland

Location

PULMAG Grzegorz Gąsior, Marzena Kociołek spółka cywilna

Sosnowiec, 41-205, Poland

Location

Centrum Medyczne Lucyna i Andrzej DymeK

Strzelce Opolskie, 47-100, Poland

Location

ALERGO-MED Specjalistyczna Przychodnia Lekarska Sp. z o. o.

Tarnów, 33-100, Poland

Location

CLINICAL BEST SOLUTIONS Fiutkowski Sp. z o.o.

Warsaw, 41-100, Poland

Location

Centrum Badań Klinicznych

Wroclaw, 51-162, Poland

Location

Michał Bogacki Dobrostan

Wroclaw, 53-301, Poland

Location

Lekarze Specjaliści - J. Małolepszy I Partnerzy

Wroclaw, 54-239, Poland

Location

Angisan Grup Srl

Bragadiru, 769764, Romania

Location

Centrul Medical Sana (SANA S.R.L.)

Bucharest, 011025, Romania

Location

National Institute of Pneumology Marius Nasta

Bucharest, 050159, Romania

Location

Medsana Bucharest Medical Center Srl

Bucharest, Romania

Location

Spitalul Clinic de Pneumoftiziologie Leon Daniello

Cluj-Napoca, 400332, Romania

Location

Spitalul Clinic de Pneumoftiziologie Leon Daniello

Cluj-Napoca, 400394, Romania

Location

Spitalul clinic de Pneumoftiziologie Palazu Mare Constanta

Constanța, 900002, Romania

Location

Spitalul Clinic de Boli Infecțioase și Pneumoftiziologie "Victor Babeș" Craiova

Craiova, 200515, Romania

Location

Spital Judetean de Urgenta Bihor

Oradea, Romania

Location

Clinical Hospital of Infectious Diseases and Pneumophysiology Dr.Victor Babeș Timișoara

Timișoara, Romania

Location

Clinical Hospital of Infectious Diseases and Pneumophysiology

Timișoara, Romania

Location

Clinic for Pulmonary Diseases, University Clinical center of Serbia

Belgrade, 11000, Serbia

Location

Municipal Institute for lung diseases and tuberculosis

Belgrade, Serbia

Location

Institute for Pulmonary Diseases of Vojvodina.

Kamenica, 21204, Serbia

Location

Clinic for Pulmonology, University Clinical Center Kragujevac.

Kragujevac, 34000, Serbia

Location

Clinic for Pulmonology, University Clinical Center Kragujevac

Kragujevac, Serbia

Location

Clinical Centre of Niš Clinic for Lung Diseases

Niš, 18000, Serbia

Location

Užice General Hospital Miloša Obrenovića 17.

Užice, 31000, Serbia

Location

Poliklinika ČK PLUS Alian s.r.o

Bardejov, 085 01, Slovakia

Location

Pľucna ambulancia MUDr. Miroslava Undesser

Dunajská Streda, 929 01, Slovakia

Location

Nemocnica s poliklinikou Š. Kukuru Michalovce

Michalovce, 071 01, Slovakia

Location

Pľúcna ambulacia - MUDr. Slavomír Hrebenár

Spišská Nová Ves, 05201, Slovakia

Location

IMUNOALERGOLÓGIA JZ, s.r.o.

Žilina, 010 01, Slovakia

Location

KOMA Kardioprax, s.r.o.

Žilina, 010 01, Slovakia

Location

Hospital General Universitario de Castellón

Castellon, 12004, Spain

Location

Giromed Institute Parc Científic i Tecnològic Universitat de Girona

Girona, 17003, Spain

Location

Hospital Universitario 12 de Octubre

Madrid, 28041, Spain

Location

Complejo Hospitalario Universitario de Santiago Hospital Clínico Universitario de Santiago

Santiago de Compostela, 15706, Spain

Location

Bradford Teaching Hospitals NHS Foundation Trust

Bradford, BD9 6RJ, United Kingdom

Location

Queen Mary University of London

London, EC1M6BQ, United Kingdom

Location

Guy's & St Thomas'NHS Foundation Trust of Royal Brompton Hospital

London, UB9 6JH, United Kingdom

Location

Medicines Evaluation Unit, Langley Building, Wythenshawe Hospital

Manchester, M23 9QZ, United Kingdom

Location

Portsmouth Hospitals University NHS Trust

Portsmouth, PO6 3LY, United Kingdom

Location

MeSH Terms

Conditions

Asthma

Condition Hierarchy (Ancestors)

Bronchial DiseasesRespiratory Tract DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Study Officials

  • Dave Singh, MD

    Medicines Evaluation Unit, Langley Building, Wythenshawe Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
Double-blind multicentre, randomised, active-controlled, 2-arm, parallel-group
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Double-blind multicentre, randomised, active-controlled, 2-arm, parallel-group
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 13, 2023

First Posted

February 20, 2024

Study Start

November 27, 2023

Primary Completion

February 18, 2025

Study Completion

February 24, 2025

Last Updated

April 14, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations